Securities Fraud Investigation Launched Against Alnylam After 28% Plunge
ALNY is trading near its 52-week low of $197.81 (12% above the low) on elevated volume (2.0× avg).
Summary
A shareholder rights law firm has opened a securities fraud investigation into Alnylam, focusing on whether the company misled investors prior to its Q2 2026 report. The probe centers on the July 30 guidance cut for TTR product sales, which triggered a 28.4% single-day stock drop. This follows the company's strong Q2 revenue of $1.29B and the AMVUTTRA launch, but the lowered outlook caught the market off guard. The investigation adds legal risk to an already volatile post-earnings situation. No specific upcoming events are known, but the stock's sharp decline and the investigation could attract further scrutiny.
At the time of this announcement, ALNY was trading at $220.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.3B. The 52-week trading range was $197.81 to $495.55. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.